Literature DB >> 18258578

Ewing's sarcoma family of tumors: an overview from diagnosis to survivorship.

Meredith Lahl1, Vicki L Fisher, Kelly Laschinger.   

Abstract

The Ewing's sarcoma family of tumors (ESFT) is a malignant primary bone tumor often involving soft tissue that affects not only children but also young adults. Since 1992, with the addition of ifosfamide and etoposide to standard chemotherapy for primary tumors, much improvement has been made in the treatment of ESFT, with a primary focus on children. Though often recognized as a childhood cancer, it can affect individuals into the middle years of their lives, but little is known about the outcomes of adults with ESFT. ESFT, which includes Ewing's sarcoma, extraosseous Ewing's sarcoma, Askin tumor, and primitive neuroectodermal tumor, is the second most common primary malignant bone tumor in children and adolescents. It accounts for 10% of primary malignant bone tumors in children and 3% of all childhood malignancies. The most common presenting symptoms of ESFT are pain or swelling. Treatment for ESFT consists of a multimodal approach, including chemotherapy, radiation therapy, and surgery. Children and young adults with Ewing's sarcoma face many physical challenges from their illness and the complications of their treatments. Nurses play an instrumental role in assessment techniques, which lead to prompt evaluation and intervention. Nurses are vital in the education and reinforcement of supportive care needs for this patient population.

Entities:  

Mesh:

Year:  2008        PMID: 18258578     DOI: 10.1188/08.CJON.89-97

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  11 in total

Review 1.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

2.  Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing's sarcoma.

Authors:  Emma Giuliani; Erin M Ellman; Rashmi Chugh; Molly B Moravek
Journal:  J Assist Reprod Genet       Date:  2019-04-05       Impact factor: 3.412

3.  High long-term local control with sacrectomy for primary high-grade bone sarcoma in children.

Authors:  Alexandre Arkader; Christine H Yang; Vernon T Tolo
Journal:  Clin Orthop Relat Res       Date:  2011-12-03       Impact factor: 4.176

4.  Effects of Socioeconomic and Geographic Factors on Outcomes in Ewing Sarcoma: A National Cancer Database Review.

Authors:  Kevin M McMahon; Thomas Nilles-Melchert; Vincent Eaton; Peter T Silberstein
Journal:  Cureus       Date:  2022-05-31

5.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

6.  Fertility preservation in young cancer patients.

Authors:  Ariel Revel; Shoshana Revel-Vilk
Journal:  J Hum Reprod Sci       Date:  2010-01

7.  High Efficacy of Preoperative Low-Dose Radiotherapy with Sanazole (AK-2123) for Extraskeletal Ewing's Sarcoma: A Case Report.

Authors:  Tomoya Sakabe; Hiroaki Murata; Eiichi Konishi; Kazutaka Koto; Naoyuki Horie; Takaaki Matsui; Yasushi Sawai; Hideya Yamazaki; Tsutomu V Kagiya; Toshikazu Kubo
Journal:  Sarcoma       Date:  2010-09-06

8.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

9.  The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.

Authors:  Aniruddha Sengupta; Mahbubur Rahman; Silvia Mateo-Lozano; Oscar M Tirado; Vicente Notario
Journal:  Int J Oncol       Date:  2013-07-12       Impact factor: 5.650

10.  Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review.

Authors:  Salvatore Pisconti; Giuseppina Della Vittoria Scarpati; Carlo Buonerba; Simona Messinese; Roberta Carella; Massimiliano Di Marzo; Giuseppe Di Lorenzo; Grazia Lazzari; Francesco Perri; Raffaele Solla
Journal:  Onco Targets Ther       Date:  2020-02-14       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.